FDA Investigator Yaharn Su
Yaharn Su has conducted inspections on 7 sites in 1 countries as of 06 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
7
Last Inspection Date:
06 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Yaharn Su:
Anastasia M Shields,
Anitha Palamakula Govada,
Azeezat M Lawal,
Catherine O Lamptey,
Christina K Theodorou,
Craig D Zagata,
David A Oluwo,
David L Chon,
Elizabeth Walther,
Emest F Bizjak,
Eric L Dong, BS,
James R Birkenstamm,
Jenny Sung,
Johnny D Nwankwo,
Jonah S Ufferfilge,
Joseph L Despins, PhD,
Juanita P Versace,
Kara J Wright,
Karen A Briggs,
Keith M Reilly,
Kenneth Nieves,
Kristina L Conroy,
Marcus A Ray,
Melissa J Garcia,
Merideth K Rose,
Mindy M Chou,
Monique Rac Lester,
Natasha Gupta,
Nebil A Oumer,
Olumide A Akinyemi,
Puspa Suresh Jayasekara,
Qin Xu,
Rachel C Harrington,
Roseline N Boateng,
Sayyem H Akbar,
Sena G Dissmeyer,
Stephanie L Shapley,
Suchan Kim,
Tajah L Blackburn,
Tekalign Wondimu,
Victoria Spivak,
William J Leonard,
Yoriann M Cabrera Bartolomei,
Young M Yoon,
Zhao Wang, PhD,
Zhong Li, PhD,
Zhongren Wu
Yaharn Su's Documents
Publish Date | Document Type | Title |
---|---|---|
December, 2023 | FDA 483 | Granules Pharmaceuticals Inc. - Form 483, 2023-12-15 |
November, 2023 | FDA 483 | WES PHARMA INC - Form 483, 2023-11-21 |
March, 2024 | FDA 483 | Sure-Biochem Laboratories, LLC - Form 483, 2024-03-08 |
October, 2023 | FDA 483 | DuPont Nutrition USA, Inc - Form 483, 2023-10-25 |
August, 2023 | FDA 483 | Washington Homeopathic Products - Form 483, 2023-08-23 |
May, 2024 | FDA 483 | Diamond Chemical Co Inc - Form 483, 2024-05-16 |
April, 2024 | FDA 483 | Eisai Inc. - Form 483, 2024-04-09 |
September, 2024 | FDA 483 | Annovex Pharma, Inc. - Form 483, 2024-09-06 |
October, 2024 | FDA 483 | Church & Dwight Co., Inc. - Form 483, 2024-10-25 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more